34162-15-7

Usage

Uses

Used in Pharmaceutical Synthesis:
2-CHLORO-N-[2-(3-CHLOROPHENYL)ETHYL]ACETAMIDE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various drugs. Its presence of chlorine and amide groups facilitates the creation of diverse medicinal compounds with potential therapeutic effects.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-CHLORO-N-[2-(3-CHLOROPHENYL)ETHYL]ACETAMIDE is utilized as a research compound to explore its potential in the development of new drugs. Its structural features may offer insights into the design of novel therapeutic agents, particularly those targeting specific biological pathways or receptors.
Used in Drug Development:
2-CHLORO-N-[2-(3-CHLOROPHENYL)ETHYL]ACETAMIDE is employed in drug development as a precursor or building block for the creation of new pharmaceutical entities. Its chemical properties may be leveraged to enhance the efficacy, selectivity, or stability of drug candidates, contributing to advancements in medical treatments.
Used in Chemical Material Design:
Beyond its pharmaceutical applications, 2-CHLORO-N-[2-(3-CHLOROPHENYL)ETHYL]ACETAMIDE may also be used in the design of chemical materials with specific properties. Its structural components could be harnessed to develop materials with tailored characteristics for use in various industries, such as coatings, adhesives, or polymers.

InChI:InChI=1/C10H11Cl2NO/c11-7-10(14)13-5-4-8-2-1-3-9(12)6-8/h1-3,6H,4-5,7H2,(H,13,14)

Upstream product

• 79-11-8 chloroacetic acid 
• 13078-79-0 2-(3-chlorophenyl)ethylamine 
• 79-04-9 chloroacetyl chloride 

Relevant academic research and scientific papers

Novel chromenyl-based 2-iminothiazolidin-4-one derivatives as tubulin polymerization inhibitors: Design, synthesis, biological evaluation and molecular modelling studies

Here-in, we present molecular design, chemical synthesis and evaluation of novel chromenyl-based 2-iminothiazolidin-4-one derivatives as tubulin polymerization inhibitors. The newly synthesized compounds were evaluated for their in vitro cytotoxicities against A549 (lung cancer), MDA-MB-231 and BT-471 (breast cancer), HepG2 (liver cancer) and HCT-116 (colon cancer) cell lines by MTT assay. Among the synthesized compounds, compound 12b showed excellent anticancer activity on MDA-MB-231 cell line with IC50 value of 0.95 ± 1.88 μM and was verified to be safe in normal human bronchial epithelial cells (Beas-2B). Apoptosis induced by the lead 12b was observed using morphological observations, AO/EB and DAPI staining procedures. Further, dose-dependent increase in the depolarization of mitochondrial membrane was also observed through JC-1 staining. Annexin V-FITC/PI assay confirmed that 12b induced early apoptosis. Additionally, cell cycle analysis indicated that the MDA-MB-231 cells were arrested at sub-G2/M phase and also inhibited tubulin polymerization with IC50 value of 3.54 ± 0.2 μM. Molecular docking simulations were employed to identify the important binding modes responsible for the tubulin inhibitory activity, thus supporting their effective anticancer potential.

Synthesis of a small library of phenylalkylamide derivatives as melatoninergic ligands for human mt1 and MT2 receptors

Focused small libraries of melatonin receptor ligands from arylalkylamine derivatives were synthesised by combinatorial chemistry using the mix and split method in the solid phase. A library of 108 compounds was then synthesised from 12 arylalkyl amines and nine carboxylic acids. The compound mixtures were evaluated on chicken brain melatonin and recombinant human mt1 and MT2 receptors. Deconvolution of the most potent mixture demonstrated the superiority of 3-methoxy and 2,5-dimethoxy substitution on the phenyl ring with isopropyl, propyl and ethyl amido chains. Several compounds with nanomolar affinity for human melatonin receptors were obtained. (C) 2000 Elsevier Science Ltd.